Newsroom
Intelligenome Announces R&D Subaward Agreement with Cornell University
Intelligenome, a global leader in CRISPR-based in vitro diagnostic (IVD) technology, is pleased to announce that it has entered into a research and development subaward agreement with Cornell University to support the development of a rapid, low-cost, portable diagnostic solution for tuberculosis (TB).
IntelliGenome Receives FDA Breakthrough Device Designation for CRISPR-TB Blood Test
IntelliGenome, an innovative molecular diagnostic solutions provider, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its CRISPR-Tuberculosis (TB) Blood Test.
